GlassScriptPhysician profile
James G Wakefield
NPI 1801882345
$7,235.67
in general payments reported to CMS, 2019-2025
40 companies · $2,167 in 2025
The $2,167 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $408 · 2020: $512 · 2021: $750 · 2022: $1,037 · 2023: $923 · 2024: $1,439 · 2025: $2,167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,508 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,508.45 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $1,541.58 | 2022-2025 | |
| Abbvie INC. | $1,300.79 | 2021-2025 | Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $1,045.74 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $291.03 | 2019-2025 | Otezla, Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $270.16 | 2020-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $268.62 | 2024-2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $241.46 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $206.59 | 2021-2024 | |
| Novo Nordisk INC | $185.87 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $175.02 | 2020-2024 | Mounjaro, Zepbound, Jardiance |
| Allergan, INC. | $171.73 | 2019-2020 | |
| Braeburn INC. | $163.97 | 2025 | Brixadi |
| E.R. Squibb & Sons, L.L.C. | $134.17 | 2020-2022 | |
| Electromed, INC. | $130.01 | 2021-2025 | Smartvest |
| Pfizer INC. | $127.77 | 2019-2024 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Wakefield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.